Issue Date: March 10, 2008
Financial Windfall From Lyrica
OF ALL THE would-be pharmaceutical agents that academic researchers study, very few turn into commercial medications. Even fewer still generate millions of dollars for the drugs' discoverers and their universities. And for a university to land a drug-related windfall at the next level up—in the billion-dollar blockbuster range—is all but unheard of. Yet Northwestern University stands to bring in that kind of wealth from its royalties on Lyrica, a pain and epilepsy medication . . .
To view the rest of this content, please log in with your ACS ID.
- Financial Windfall From Lyrica
- Royalty payouts from university-held patents have power to transform chemistry departments
- Drug Discovery
- Long Haul From Fundamental Research To Blockbuster Drug
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society